NY-IFF
1.2.2021 12:52:11 CET | Business Wire | Press release
IFF (NYSE: IFF) today launched a bold new brand identity designed to propel the Company’s transformation and reinforce its leadership role in the global value chain for consumer goods and commercial products. Upon the completion of its combination with DuPont’s Nutrition & Biosciences (N&B) business, IFF will begin a new era guided by an authentic customer-centric approach and commitment to execution, deep R&D and innovation capabilities, a storied legacy of artistry and a passion to be an essential partner for its customers around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005398/en/
As part of the new brand identity, IFF has launched a new tagline, purpose, brand commitments, and cultural attributes and values. The Company believes that these brand components will support the success of the four divisions that now comprise the new IFF.
IFF’s new brand identity and tagline : Where science and creativity meet , captures the company’s longstanding focus on the dynamic interplay between artistry and science to deliver differentiated, integrated solutions to customers that amaze and delight. IFF is a force for good in its communities worldwide, accelerating sustainability-driven change across its industry.
The company’s purpose , Applying science and creativity for a better world , continues to inspire everyone at IFF to push past traditional industry boundaries and commits to be a force for a better and more sustainable future.
Core to the company’s strategy for success, a central vision: Be the partner for essential solutions , reflects its vital leadership role in the global value chain for consumer goods and commercial products, and deep commitment to be guided by a customer-centric approach in everything we do.
The IFF brand continues to be underpinned by three commitments , adapted to better reflect the new organization.
- Question Everything : We’re here to shake things up and forge a new path. We’re working at the cutting edge of artistry and science and encourage new discoveries at every opportunity.
- Champion Creators : We believe our differences make us great. We power companies of every shape, size and style with the ingredients, solutions and passion to convert ideas into impact.
- Do More Good : Claiming perfection doesn’t help. We’re on a journey to do better for people and planet. Every day we bring the talent, influence and responsibility to constantly challenge the status quo.
“Today we start a transformative journey together to become a center of innovation for our customers,” said Andreas Fibig, IFF Chairman and Chief Executive Officer. “Our leadership team believes passionately in the importance and benefit of being a purpose-driven enterprise. We will lead not simply by relying on an unmatched portfolio and flawless execution, but by quickly unlocking new innovations as we tap into our shared passion for pairing science and creativity to deliver for our customers. We are creating an agile, empowered and innovative business that provides exceptional service and delivers on our commitment to be an essential partner for our customers.”
Mr. Fibig continued, “Critical to our success is our ability to foster an execution culture and embed values that support our promises to our people, customers, consumers and our communities. To that end, we have updated our cultural principles to ensure we have the foundation in place to empower our people to deliver on our commitments.”
IFF’s merger with N&B prompted the Company to establish a new set of core values and cultural principles as the foundation of its growth strategy. This resulted in the following cultural principles :
- ACT AS AN OWNER: We take ownership and work with passion and integrity. Our teams are empowered to make decisions and help the entire organization thrive.
- BE AGILE: We constantly push for progress and respond to the needs of our customers and the world with speed, skill, and creativity.
- COLLABORATE AND WIN TOGETHER: Our bond with our customers and colleagues powers innovation and our shared success.
IFF’s culture is further buoyed by its values:
- Empowerment: We make informed decisions, take action and have the courage to hold ourselves accountable for the outcomes.
- Expertise: We collaborate, applying our collective skills and diverse backgrounds to solve problems and achieve higher levels of performance.
- Integrity: We are inclusive, treat each other with respect and work in a fair, honest and ethical way.
- Innovation: We harness our creativity to deliver essential solutions for our partners and the communities we serve.
- Responsibility: We protect the health and safety of our people and preserve the communities where we work.
Introducing IFF’s Business Divisions
Nourish
The Company announced its combined Taste, Food & Beverage division will now be called Nourish.
To nourish is to feed with purpose
, a vision that guides IFF’s partnership with all stakeholders. Nourish, IFF’s largest division, is composed of IFF’s Taste division and N&B’s Food & Beverage segment. The new identity for Nourish better aligns the division with the enhanced capabilities, vision and purpose of the combined company as Nourish boldly imagines to create the future of food and beverage experiences.
Scent
IFF’s Scent division creates and pioneers unique fragrances, scent solutions and cosmetic actives across key consumer goods industries such as fine perfumery, personal, fabric and home care. Key enablers to these pioneering scents are unique fragrance ingredients and naturals which bring breakthrough olfactive innovation and augmented perfumery benefits. Scent leads fragrance artistry, scientific discovery and therapeutic breakthroughs that change the word for better by awakening human nature.
Health & Biosciences
Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Bioscience (H&B) platform is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. H&B works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions.
Pharma Solutions
IFF’s Pharma Solutions division is a trusted leader in developing the ingredients, products and applications that support global production of pharma and dietary supplements. With recognized brands and unmatched expertise, Pharma Solutions is setting new standards in a highly regulated industry.
To view IFF’s new brand video, visit this link . For more information about IFF’s new era at the intersection of science and creativity, visit iff.com .
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and sensorial experiences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005398/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
